A Comprehensive Study Of Non-Alcoholic Fatty Liver Disorder Literature Review

Maged Naser, Mohamed M. Nasr, Lamia H. Shehata

Abstract


The prevalence of non-alcoholic fatty liver disorder (NAFLD) spans approximately 25% globally. The rate of occurrence is on the rise due to escalating rates of obesity, type 2 diabetes, and the metabolic syndrome. It is anticipated that NAFLD will emerge as the primary cause of cirrhosis necessitating liver transplants in the upcoming decade. Nevertheless, cardiovascular ailments remain the leading cause of mortality, and only a small fraction of individuals will develop fibrosis and liver associated complications. Hence, it is crucial to identify patients with progressive disease using non-invasive fibrosis markers, which encompass serology based assess-ents (e.g., NAFLD Fibrosis Score and ELF test) and imaging techniques (e.g., transient elastography). This approach aims to pinpoint suitable candidates for refer-al to secondary care for further evaluations like liver biopsy and expert assistance. Adjustments in lifestyle and weight reduction continue to be the foundation of treatment, yet we are poised to embark on a new phase of hopeful pharmacological therapies for NASH and fibrosis.Keywords: Non-Alcoholic Fatty Liver Disease, Fibrosis, Diagnosis, Management, Liver Disease


Keywords


Non-Alcoholic Fatty Liver Disease, Fibrosis, Diagnosis, Management, Liver Disease

Full Text:

PDF

References


- Younossi, Zobair M., et al. "Global epidemiology of nonalcoholic fatty liver disease—meta‐analytic assessment of prevalence, incidence, and outcomes." Hepatology 64.1 (2016): 73-84.

- Ghevariya, Vishal, et al. "Knowing what’s out there: awareness of non-alcoholic fatty liver disease." Frontiers in Medicine 1 (2014): 4.

- Bambha, Kiran, et al. "Ethnicity and nonalcoholic fatty liver disease." Hepatology 55.3 (2012): 769-780.

- Romeo, Stefano, et al. "Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease." Nature genetics 40.12 (2008): 1461-1465.

- Eslam, Mohammed, et al. "The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease." Hepatology international 14 (2020): 889-919.

- Ekstedt, Mattias, et al. "Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up." Hepatology 61.5 (2015): 1547-1554.

- Angulo, Paul, et al. "Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease." Gastroenterology 149.2 (2015): 389-397.

- Dulai, Parambir S., et al. "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta‐analysis." Hepatology 65.5 (2017): 1557-1565.

- Singh, Siddharth, et al. "Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies." Clinical gastroenterology and hepatology 13.4 (2015): 643-654.

- Angulo, Paul, et al. "The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD." Hepatology 45.4 (2007): 846-854.

- Sinn, Dong Hyun, et al. "Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study." Gut 66.2 (2017): 323-329.

- Wong, Robert J., et al. "Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States." Gastroenterology 148.3 (2015): 547-555.

- Charlton, Michael R., et al. "Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States." Gastroenterology 141.4 (2011): 1249-1253.

- Mittal, Sahil, et al. "Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease." Clinical Gastroenterology and Hepatology 14.1 (2016): 124-131.

- Zeng, Han, et al. "CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing." Molecular metabolism 57 (2022): 101428.

- Lu, Yang, et al. "HBx induced upregulation of FATP2 promotes the development of hepatic lipid accumulation." Experimental Cell Research 430.1 (2023): 113721.

- Blériot, Camille, et al. "A subset of Kupffer cells regulates metabolism through the expression of CD36." Immunity 54.9 (2021): 2101-2116.

- Lee, Yo Han, et al. "Hepatic MIR20B promotes nonalcoholic fatty liver disease by suppressing PPARA." Elife 10 (2021): e70472.

- Nie, Kexin, et al. "Diosgenin attenuates non-alcoholic fatty liver disease in type 2 diabetes through regulating SIRT6-related fatty acid uptake." Phytomedicine 111 (2023): 154661.

- Dille, Matthias, et al. "Long-term adjustment of hepatic lipid metabolism after chronic stress and the role of FGF21." Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1868.1 (2022): 166286.

- Li, Xinzhi, et al. "The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression." Nature communications 12.1 (2021): 7213.

- Sozen, Erdi, et al. "Deficiency of SREBP1c modulates autophagy mediated lipid droplet catabolism during oleic acid induced steatosis." Metabolism Open 12 (2021): 100138.

- Zhu, Chaoyu, et al. "SIRT6 controls hepatic lipogenesis by suppressing LXR, ChREBP, and SREBP1." Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1867.12 (2021): 166249.

- Yang, Yanying, et al. "Improvement of MASLD and MASH by suppression of hepatic N-acetyltransferase 10." Molecular Metabolism 89 (2024): 102030.

- Li, Yan-Ling, et al. "Identification of Metabolism-Related Proteins as Biomarkers of Insulin Resistance and Potential Mechanisms of m6A Modification." Nutrients 15.8 (2023): 1839.

- Zywno, Hubert, et al. "The influence of coumestrol on sphingolipid signaling pathway and insulin resistance development in primary rat hepatocytes." Biomolecules 11.2 (2021): 268.

- Khoury, Mireille, et al. "Glycogen synthase kinase 3 activity enhances liver inflammation in MASH." JHEP Reports 6.6 (2024): 101073.

- Li, Xiao-Yun, et al. "Regulation of PPAR-γ activity in lipid-laden hepatocytes affects macrophage polarization and inflammation in nonalcoholic fatty liver disease." World Journal of Hepatology 14.7 (2022): 1365.

- Theys, Claudia, et al. "Loss of PPARα function promotes epigenetic dysregulation of lipid homeostasis driving ferroptosis and pyroptosis lipotoxicity in metabolic dysfunction associated Steatotic liver disease (MASLD)." Frontiers in molecular medicine 3 (2024): 1283170.

- Régnier, Marion, et al. "Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity." Scientific reports 10.1 (2020): 6489.

- Hu, Sha, et al. "USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination." Clinical and Molecular Hepatology 31.1 (2024): 147.

- Moliterni, Camilla, et al. "Lipotoxicity of palmitic acid is associated with DGAT1 downregulation and abolished by PPARα activation in liver cells." Journal of Lipid Research 65.12 (2024): 100692.

- Selvaraj, Rajakumar, et al. "Preferential lipolysis of DGAT1 over DGAT2 generated triacylglycerol in Huh7 hepatocytes." Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids 1868.10 (2023): 159376.

- Rong, Shunxing, et al. "DGAT2 inhibition blocks SREBP-1 cleavage and improves hepatic steatosis by increasing phosphatidylethanolamine in the ER." Cell metabolism 36.3 (2024): 617-629.

- Lima, Nátalia da Silva, et al. "Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function."

- Jiang, Jing, et al. "Upregulation of hepatic glutathione s-transferase alpha 1 ameliorates metabolic dysfunction-associated steatosis by degrading fatty acid binding protein 1." International Journal of Molecular Sciences 25.10 (2024): 5086.

- Piccinin, Elena, et al. "Intestinal Pgc1α ablation protects from liver steatosis and fibrosis." JHEP Reports 5.11 (2023): 100853.

- Ni, Yinhua, et al. "CX3CL1/CX3CR1 interaction protects against lipotoxicity-induced nonalcoholic steatohepatitis by regulating macrophage migration and M1/M2 status." Metabolism 136 (2022): 155272.

- Yang, Wei, et al. "Regulation of cholesterol metabolism during high fatty acid–induced lipid deposition in calf hepatocytes." Journal of Dairy Science 106.8 (2023): 5835-5852.

- Chen, Zhouji, et al. "Conditional hepatocyte ablation of PDIA1 uncovers indispensable roles in both APOB and MTTP folding to support VLDL secretion." Molecular Metabolism 80 (2024): 101874.

- Hou, Tianyun, et al. "Cytoplasmic SIRT6-mediated ACSL5 deacetylation impedes nonalcoholic fatty liver disease by facilitating hepatic fatty acid oxidation." Molecular Cell 82.21 (2022): 4099-4115.

- Huang, Dong, et al. "TMEM41B acts as an ER scramblase required for lipoprotein biogenesis and lipid homeostasis." Cell metabolism 33.8 (2021): 1655-1670.

- Strøm, Thea Bismo, et al. "Missense mutation Q384K in the APOB gene affecting the large lipid transfer module of apoB reduces the secretion of apoB-100 in the liver without reducing the secretion of apoB-48 in the intestine." Journal of Clinical Lipidology 17.6 (2023): 800-807.

- Xu, Yanyong, et al. "Hepatocyte ATF3 protects against atherosclerosis by regulating HDL and bile acid metabolism." Nature metabolism 3.1 (2021): 59-74.

- Zhao, Ke, et al. "Adipokines regulate the development and progression of MASLD through organellar oxidative stress." Hepatology Communications 9.2 (2025): e0639.

- Dong, Zhixia, et al. "Adiponectin inhibits NLRP3 inflammasome activation in nonalcoholic steatohepatitis via AMPK-JNK/ErK1/2-NFκB/ROS signaling pathways." Frontiers in medicine 7 (2020): 546445.

- Zhou, Mingyan, et al. "Upregulation of UCP2 by adiponectin: the involvement of mitochondrial superoxide and hnRNP K." PloS one 7.2 (2012): e32349.

- Chatterjee, Saurabh, et al. "Leptin is key to peroxynitrite-mediated oxidative stress and Kupffer cell activation in experimental non-alcoholic steatohepatitis." Journal of hepatology 58.4 (2013): 778-784.

- Chau, Mary DL, et al. "Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK–SIRT1–PGC-1α pathway." Proceedings of the National Academy of Sciences 107.28 (2010): 12553-12558.

- Yu, Yinhang, et al. "Fibroblast growth factor (FGF21) protects mouse liver against D-galactose-induced oxidative stress and apoptosis via activating Nrf2 and PI3K/Akt pathways." Molecular and cellular biochemistry 403 (2015): 287-299.

- Liu, Yan, et al. "Retinol-binding protein 4 induces hepatic mitochondrial dysfunction and promotes hepatic steatosis." The Journal of Clinical Endocrinology & Metabolism 101.11 (2016): 4338-4348.

- Yao, Jin-Mei, et al. "Exosomal RBP4 potentiated hepatic lipid accumulation and inflammation in high-fat-diet-fed mice by promoting M1 polarization of Kupffer cells." Free Radical Biology and Medicine 195 (2023): 58-73.

- Park, Min-Jung, et al. "New role of irisin in hepatocytes: The protective effect of hepatic steatosis in vitro." Cellular signalling 27.9 (2015): 1831-1839.

- Batirel, Saime, et al. "The effect of Irisin on antioxidant system in liver." Free Radic Biol Med 75.Suppl 1 (2014): S16.

- Pohl, Rebekka, et al. "Chemerin overexpression in the liver protects against inflammation in experimental non-alcoholic steatohepatitis." Biomedicines 10.1 (2022): 132.

- Nakatsuka, Atsuko, et al. "Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex." Diabetes 61.11 (2012): 2823-2832.

- Li, Cheng, et al. "The role of apelin–APJ system in diabetes and obesity." Frontiers in endocrinology 13 (2022): 820002.

- Han, Dongli, et al. "Serum resistin levels in adult patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis." Journal of Clinical and Translational Hepatology 9.4 (2021): 484.

- Heo, Yu Jung, et al. "Visfatin induces inflammation and insulin resistance via the NF‐κB and STAT3 signaling pathways in hepatocytes." Journal of diabetes research 2019.1 (2019): 4021623.

- de la Garza, Rocio G., et al. "Insulin-like growth factor-1 deficiency and cirrhosis establishment." Journal of clinical medicine research 9.4 (2017): 233.

- Lee, Eunjung, et al. "Stachydrine derived from fermented rice prevents diet-induced obesity by regulating adipsin and endoplasmic reticulum homeostasis." The Journal of nutritional biochemistry 107 (2022): 109036.

- Gu, Naibing, et al. "The effects of intelectin-1 on antioxidant and angiogenesis in HUVECs exposed to oxygen glucose deprivation." Frontiers in Neurology 10 (2019): 383.

- Skuratovskaia, Daria, et al. "IL-6 reduces mitochondrial replication, and IL-6 receptors reduce chronic inflammation in NAFLD and type 2 diabetes." International Journal of Molecular Sciences 22.4 (2021): 1774.

- Dong, Jinrui, et al. "Hepatocyte-specific IL11 cis-signaling drives lipotoxicity and underlies the transition from NAFLD to NASH." Nature communications 12.1 (2021): 66.

- Li, Shuo, et al. "SOCS2 suppresses inflammation and apoptosis during NASH progression through limiting NF-κB activation in macrophages." International Journal of Biological Sciences 17.15 (2021): 4165.

- Guan, Canghai, et al. "Metallothionein 1B attenuates inflammation and hepatic steatosis in MASH by inhibiting the AKT/PI3K pathway." Journal of Lipid Research 66.1 (2025): 100701.

- Yu, Yongsheng, et al. "STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis." The Journal of clinical investigation 129.2 (2019): 546-555.

- Wu, Yue, et al. "Oxidative stress linked organ lipid hydroperoxidation and dysregulation in mouse model of nonalcoholic steatohepatitis: Revealed by lipidomic profiling of liver and kidney." Antioxidants 10.10 (2021): 1602.

- Rauchbach, Einat, et al. "Cholesterol induces oxidative stress, mitochondrial damage and death in hepatic stellate cells to mitigate liver fibrosis in mice model of NASH." Antioxidants 11.3 (2022): 536.

- Vargas-Pozada, Eduardo E., et al. "Caffeine inhibits NLRP3 inflammasome activation by downregulating TLR4/MAPK/NF-κB signaling pathway in an experimental NASH model." International Journal of Molecular Sciences 23.17 (2022): 9954.

- Neira, Gabriela, et al. "FNDC4 reduces hepatocyte inflammatory cell death via AMPKα in metabolic dysfunction-associated steatotic liver disease." Clinical Nutrition 43.9 (2024): 2221-2233.

- Kim, Hyeon Ju, et al. "GPx7 ameliorates non-alcoholic steatohepatitis by regulating oxidative stress." BMB reports 53.6 (2020): 317.

- An, Xiuqin, et al. "Chemerin/CMKLR1 ameliorates nonalcoholic steatohepatitis by promoting autophagy and alleviating oxidative stress through the JAK2-STAT3 pathway." Peptides 135 (2021): 170422.

- Remmerie, Anneleen, et al. "Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the fatty liver." Immunity 53.3 (2020): 641-657.

- Seidman, Jason S., et al. "Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis." Immunity 52.6 (2020): 1057-1074.

- Tran, Sophie, et al. "Impaired Kupffer cell self-renewal alters the liver response to lipid overload during non-alcoholic steatohepatitis." Immunity 53.3 (2020): 627-640.

- Xu, Dongwei, et al. "The Foxo1-YAP-Notch1 axis reprograms STING-mediated innate immunity in NASH progression." Experimental & molecular medicine 56.8 (2024): 1843-1855.

- Song, Kyoungsub, et al. "Yes‐Associated protein in Kupffer cells enhances the production of proinflammatory cytokines and promotes the development of nonalcoholic steatohepatitis." Hepatology 72.1 (2020): 72-87.

- Ajaz, Saima, et al. "Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD)." Mitochondrion 57 (2021): 119-130.

- Moore, Mary P., et al. "Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD." Hepatology 76.5 (2022): 1452-1465.

- Frietze, Karla K., et al. "Lipotoxicity reduces DDX58/Rig-1 expression and activity leading to impaired autophagy and cell death." Autophagy 18.1 (2022): 142-160.

- Qin, Yuanyuan, et al. "Loss of TMEM55B modulates lipid metabolism through dysregulated lipophagy and mitochondrial function." bioRxiv (2024): 2024-11.

- Steffen, Janos, et al. "The mitochondrial fission protein Drp1 in liver is required to mitigate NASH and prevents the activation of the mitochondrial ISR." Molecular Metabolism 64 (2022): 101566.

- Yamada, Tatsuya, et al. "Prevention and regression of megamitochondria and steatosis by blocking mitochondrial fusion in the liver." Iscience 25.4 (2022).

- Chen, Mingtai, et al. "A classical herbal formula alleviates high-fat diet induced nonalcoholic steatohepatitis (NASH) via targeting mitophagy to rehabilitate dysfunctional mitochondria, validated by UPLC-HRMS identification combined with in vivo experiment." Biomedicine & Pharmacotherapy 168 (2023): 115831.

- Ding, Nan, et al. "AGK regulates the progression to NASH by affecting mitochondria complex I function." Theranostics 12.7 (2022): 3237.

- Peyman, Mona, et al. "SIRT1 regulates hepatic vldlr levels." Cell Communication and Signaling 22.1 (2024): 297.

- Jin, Shengxi, et al. "Phocaeicola vulgatus alleviates diet-induced metabolic dysfunction-associated steatotic liver disease progression by downregulating histone acetylation level via 3-HPAA." Gut Microbes 16.1 (2024): 2309683.

- Roy, Subhajit, et al. "Hepatic NLRP3-Derived Hsp70 binding to TLR4 mediates MASLD to MASH Progression upon Inhibition of PP2A by Harmful Algal Bloom Toxin Microcystin, a second hit." International journal of molecular sciences 24.22 (2023): 16354.

- Zeng, Xin, et al. "Oleic acid ameliorates palmitic acid induced hepatocellular lipotoxicity by inhibition of ER stress and pyroptosis." Nutrition & metabolism 17.1 (2020): 11.

- Kochumon, Shihab, et al. "Gut dysbiosis shaped by cocoa butter-based sucrose-free HFD leads to steatohepatitis, and insulin resistance in mice." Nutrients 16.12 (2024): 1929.

- Zhang, Liting, et al. "TLR2 inhibition ameliorates the amplification effect of LPS on lipid accumulation and lipotoxicity in hepatic cells." Annals of Translational Medicine 9.18 (2021): 1429.

- Didenko, V. I., et al. "Specificities of lipotoxicity of free fatty acids and cytokine profile in patients with chronic diffuse liver diseases." Regulatory Mechanisms in Biosystems 13.1 (2022): 3-9.

- Yin, Yue, et al. "Ghrelin ameliorates nonalcoholic steatohepatitis induced by chronic low‐grade inflammation via blockade of Kupffer cell M1 polarization." Journal of cellular physiology 236.7 (2021): 5121-5133.

- Xu, Qing, et al. "Suppression of STK39 weakens the MASLD/MASH process by protecting the intestinal barrier." BioScience Trends 18.3 (2024): 289-302.

- Sarkar, Ankita, et al. "Butyrate limits inflammatory macrophage niche in NASH." Cell death & disease 14.5 (2023): 332.

- Helgesson, Samuel, et al. "Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis." Heliyon 10.8 (2024).

- Kutaiba, Numan, et al. "The impact of hepatic and splenic volumetric assessment in imaging for chronic liver disease: a narrative review." Insights into Imaging 15.1 (2024): 146.

- Zhang, Shaoying, et al. "CD11b+ CD43hiLy6Clo splenocyte‐derived macrophages exacerbate liver fibrosis via spleen–liver axis." Hepatology 77.5 (2023): 1612-1629.

- Sherman, David J., et al. "The fatty liver disease–causing protein PNPLA3-I148M alters lipid droplet–Golgi dynamics." Proceedings of the National Academy of Sciences 121.18 (2024): e2318619121.

- Fernández-Tussy, Pablo, et al. "miR-33 deletion in hepatocytes attenuates MASLD-MASH-HCC progression." JCI insight 9.19 (2024): e168476.

- Theys, Claudia, et al. "Mitochondrial GpC and CpG DNA hypermethylation cause metabolic stress-induced mitophagy and cholestophagy." International journal of molecular sciences 24.22 (2023): 16412.

- Younossi, Zobair M., et al. "Fatigue and pruritus in patients with advanced fibrosis due to nonalcoholic steatohepatitis: the impact on patient‐reported outcomes." Hepatology Communications 4.11 (2020): 1637-1650.

- Younossi, Zobair M., et al. "The potential role of fatigue in identifying patients with NASH and advanced fibrosis who experience disease progression." Clinical Gastroenterology and Hepatology 21.4 (2023): 970-977.

- Vidal-Cevallos, Paulina, et al. "Occult liver disease: a multinational perspective." Annals of Hepatology 29.3 (2024): 101480.

- Doward, Lynda C., et al. "Development of a patient-reported outcome measure for non-alcoholic steatohepatitis (NASH-CHECK): results of a qualitative study." The Patient-Patient-Centered Outcomes Research 14.5 (2021): 533-543.

- Bandyopadhyay, Sanjay, et al. "Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis." Diabetes & Metabolic Syndrome: Clinical Research & Reviews 17.10 (2023): 102849.

- Younossi, Zobair M., et al. "The impact of fatigue on mortality of patients with non-alcoholic fatty liver disease (NAFLD): data from National Health and nutrition examination survey (NHANES) 2005-2010 and 2017-2018." Liver Int (2022).

- Lee, Han Ah, Hye Ah Lee, and Hwi Young Kim. "Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms." Scientific Reports 14.1 (2024): 28951.

- Lee, Han Ah, Hye Ah Lee, and Hwi Young Kim. "Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms." Scientific Reports 14.1 (2024): 28951.

- Rao, Guocheng, et al. "Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic." Frontiers in medicine 10 (2023): 1294267.

- Jaffar, Hafiza Madiha, et al. "Impact of silymarin‐supplemented cookies on liver enzyme and inflammatory markers in non‐alcoholic fatty liver disease patients." Food Science & Nutrition 12.10 (2024): 7273-7286.

- Rinella, Mary E., et al. "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease." Hepatology 77.5 (2023): 1797-1835.

- Besutti, Giulia, et al. "Accuracy of imaging methods for steatohepatitis diagnosis in non‐alcoholic fatty liver disease patients: A systematic review." Liver International 39.8 (2019): 1521-1534.

- Arzehgar, Afrooz, et al. "Non-Alcoholic Fatty Liver Disease Diagnosis with Multi-Group Factors." Healthcare Transformation with Informatics and Artificial Intelligence. IOS Press, 2023. 503-506.

- Kjærgaard, Kristoffer, et al. "Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation." JHEP Reports 6.3 (2024): 100992.

- Jerome, Nirupama Esther, Nancy E. Edwards, and Qinglan Priscilla Ding. "Impact of mediterranean dietary education on symptoms for adults at risk for nonalcoholic fatty liver disease." Gastroenterology Nursing 46.5 (2023): 359-370.

- Fernández-Garibay, Valeria Michelle, and Norberto C. Chavez-Tapia. "The rationale for the aggressive progression of MASLD in patients with type 2 diabetes." Annals of Hepatology 30.1 (2025): 101778.

- Salva-Pastor, Nicolás, et al. "The diagnostic and initial approach of the patient with non-alcoholic fatty liver disease: role of the primary care provider." Gastroenterology and hepatology from bed to bench 12.4 (2019): 267.

- Nadolsky, Karl, et al. "Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey." Annals of Medicine 55.1 (2023): 2211349.

- Mascaró, Catalina M., et al. "Association between stages of hepatic steatosis and physical activity performance in adults with metabolic syndrome: A cross-sectional analysis in FLIPAN Study." Nutrients 14.9 (2022): 1790.

- Newsome, Philip N., et al. "FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study." The lancet Gastroenterology & hepatology 5.4 (2020): 362-373.

- Armandi, Angelo, and Elisabetta Bugianesi. "Extrahepatic outcomes of nonalcoholic fatty liver disease: Cardiovascular diseases." Clinics in Liver Disease 27.2 (2023): 239-250.

- Lazarus, Jeffrey V., et al. "A social media listening study of patients’ experiences relating to metabolic dysfunction-associated steatotic liver disease: the LISTEN-MASLD study." Annals of Hepatology 30.1 (2025): 101741.

- Mansour, Asieh, et al. "Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled, clinical trial." Nutrition journal 20.1 (2021): 35.

- Giannotti, Laura, et al. "Coffee Bioactive N‐Methylpyridinium: Unveiling Its Antilipogenic Effects by Targeting De Novo Lipogenesis in Human Hepatocytes." Molecular Nutrition & Food Research 68.21 (2024): 2400338.

- Hayat, Umar, et al. "The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies." Annals of hepatology 20 (2021): 100254.

- Laursen, Tea L., et al. "Bariatric surgery in patients with non-alcoholic fatty liver disease-from pathophysiology to clinical effects." World journal of hepatology 11.2 (2019): 138.

- Lassailly, Guillaume, et al. "Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis." Gastroenterology 159.4 (2020): 1290-1301.

- Pais, Raluca, et al. "Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery." Hepatology 76.2 (2022): 456-468.

- Pais, Raluca, et al. "Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery." Hepatology 76.2 (2022): 456-468.

- Armstrong, Matthew J., et al. "Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials." Diabetes, Obesity and Metabolism 27.2 (2025): 710-718.

- Fishman, Jesse, et al. "Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)." Journal of Medical Economics 27.1 (2024): 1108-1118.

- Powell, Elizabeth E. "A new treatment and updated clinical practice guidelines for MASLD." Nature Reviews Gastroenterology & Hepatology 22.2 (2025): 88-89.

- Harrison, Stephen A., et al. "A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis." New England Journal of Medicine 390.6 (2024): 497-509.

- Vidal-Cevallos, Paulina, and Norberto Chávez-Tapia. "Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis?." Med 5.5 (2024): 375-376.

- Iwaki, Michihiro, et al. "Pemafibrate for treating MASLD complicated by hypertriglyceridaemia: a multicentre, open-label, randomised controlled trial study protocol." BMJ open 14.11 (2024): e088862.

- Siddiqui, Mohammad Shadab, et al. "Saroglitazar, a dual PPAR α/γ agonist, improves atherogenic dyslipidemia in patients with non-cirrhotic nonalcoholic fatty liver disease: a pooled analysis." Clinical Gastroenterology and Hepatology 21.10 (2023): 2597-2605.

- Han, Eugene, et al. "Efficacy and safety of evogliptin in patients with type 2 diabetes and non‐alcoholic fatty liver disease: A multicentre, double‐blind, randomized, comparative trial." Diabetes, Obesity & Metabolism 24.4 (2022).

- Hirayama, Kiichi, et al. "Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub‐analysis of a randomized controlled study." Diabetes, Obesity and Metabolism 27.4 (2025): 2059-2069.

- Shi, Mengran, et al. "Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease." Journal of Diabetes and its Complications 37.10 (2023): 108610.

- Ito, Daisuke, et al. "Long‐term effects of ipragliflozin and pioglitazone on metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow‐up of a randomized, 24 week, active‐controlled trial: effect of ipragliflozin in MASLD." Journal of Diabetes Investigation 15.9 (2024): 1220-1230.

- Harrison, Stephen A., et al. "Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study." Nature medicine 28.7 (2022): 1432-1438.

- Nagao, Mototsugu, et al. "Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study." Cardiovascular Diabetology 23.1 (2024): 56.

- Koshino, Akihiko, et al. "Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial." Diabetes, Obesity and Metabolism 25.5 (2023): 1413-1418.

- Khaliq, Adil, et al. "The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: A randomized controlled trial." Medicine 103.45 (2024): e40356.

- Ratziu, Vlad, et al. "EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study." Journal of Hepatology 76.3 (2022): 506-517.

- Paternostro, Rafael, and Michael Trauner. "Current treatment of non‐alcoholic fatty liver disease." Journal of internal medicine 292.2 (2022): 190-204.

- Ratziu, Vlad, et al. "Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH." Journal of hepatology 78.3 (2023): 479-492.

- Alkhouri, Naim, et al. "Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial." Journal of hepatology 77.3 (2022): 607-618.

- Alkhouri, Naim, et al. "Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH." Liver International 44.4 (2024): 966-978.

- Liu, Chuanfeng, et al. "Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two‐Centre Open, Single‐Arm Trial." Endocrinology, Diabetes & Metabolism 8.1 (2025): e70021.

- Guo, Wen, et al. "Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial." Diabetes research and clinical practice 170 (2020): 108487.

- Gastaldelli, Amalia, et al. "Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes." Diabetes, Obesity and Metabolism 22.3 (2020): 393-403.

- Parker, Victoria ER, et al. "Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes." Nature metabolism 5.12 (2023): 2086-2093.

- Fan, Yujuan, et al. "Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open‐label, controlled trial." Diabetes, Obesity and Metabolism 26.2 (2024): 772-776.

- Newsome, Philip N., et al. "Semaglutide 2.4 mg in participants with metabolic dysfunction‐associated steatohepatitis: baseline characteristics and Design of the Phase 3 ESSENCE trial." Alimentary Pharmacology & Therapeutics 60.11-12 (2024): 1525-1533.

- Harrison, Stephen A., et al. "Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study." Journal of Hepatology 82.1 (2025): 7-17.

- Vuppalanchi, Raj, et al. "Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy to reduce screen failures." Alimentary Pharmacology & Therapeutics 60.1 (2024): 17-32.

- Sanyal, Arun J., et al. "Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial." Nature medicine 30.7 (2024): 2037-2048.

- Lawitz, Eric J., et al. "Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis." Journal of Hepatology 81.5 (2024): 837-846.

- Abdelmalek, Manal F., et al. "A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis–study design and rationale of HM-TRIA-201 study." Contemporary Clinical Trials 130 (2023): 107176.

- ElKabbany, Zeinab Anwar, et al. "The impact of vildagliptin as an add‐on therapy on matrix metalloproteinase‐14 levels, liver stiffness and subclinical atherosclerosis in adolescents with type 1 diabetes and non‐alcoholic steatohepatitis: A randomized controlled trial." Diabetes, Obesity and Metabolism 26.12 (2024): 5857-5869.

- Johansson, Lars, et al. "Dapagliflozin plus saxagliptin add‐on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes." Diabetes, Obesity and Metabolism 22.7 (2020): 1094-1101.

- Abdelmalek, Manal F., et al. "Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study." Clinical Gastroenterology and Hepatology 22.1 (2024): 113-123.

- Tseng, Chih‐Ming Leo, et al. "Population pharmacokinetics and pharmacodynamics of pegozafermin in patients with nonalcoholic steatohepatitis." Clinical Pharmacology & Therapeutics 114.6 (2023): 1323-1331.

- Harrison, Stephen A., et al. "Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial." The Lancet Gastroenterology & Hepatology 8.12 (2023): 1080-1093.

- Rinella, Mary E., et al. "A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis." Hepatology 79.3 (2024): 674-689.

- Athyros, Vasilios G., et al. "Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis." The Lancet 376.9756 (2010): 1916-1922.

- Wang, Xuan, et al. "Impact of rosuvastatin on metabolic syndrome patients with moderate to severe metabolic associated fatty liver disease without overt diabetes: A randomized clinical trial." Diabetes & Metabolic Syndrome: Clinical Research & Reviews 18.9 (2024): 103126.

- Virani, Salim S., et al. "2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines." Journal of the American College of Cardiology 82.9 (2023): 833-955.

- Huang, Yuanshe, et al. "Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology." Medicine 101.43 (2022): e31437.

- Ratziu, V., et al. "Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial." Nature medicine 27.10 (2021): 1825-1835.

- Baker, Holly. "Selonsertib ineffective in NASH." (2020): 436-436.

- Saxena, Aditi R., et al. "A phase 2a, randomized, double‐blind, placebo‐controlled, three‐arm, parallel‐group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF‐06835919 in patients with non‐alcoholic fatty liver disease and type 2 diabetes." Diabetes, Obesity and Metabolism 25.4 (2023): 992-1001.




DOI: http://dx.doi.org/10.52155/ijpsat.v52.1.7407

Refbacks

  • There are currently no refbacks.


Copyright (c) 2025 Maged Naser

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.